CNCE News and Press, Concert Pharmaceuticals Inc. From 08/22/22

Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that results from the first Phase 3 clinical trial of CTP-543 (THRIVE-AA1) in adult patients with moderate to severe alopecia areata will be presented as a late breaking oral presentation at the 31 st European Academy ...

Exercise Relates to Remaining Tranche 1 Warrants Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that BVF Partners L.P. and RA Capital Management have exercised their remaining tranche 1 warrants issued in connection with the Company’s November 20...

News of a successful Phase 2 trial for CinCor Pharma’s ( NASDAQ: CNCE ) lead asset baxdrostat sent the company shares ~50% higher on Monday towards a 52-week high as Oppenheimer cheered the experimental drug for treatment-resistant hypertension. The BrigHtn tria...

Concert Pharmaceuticals, Inc. (CNCE) Q2 2022 Earnings Conference Call August 04, 2022, 08:30 AM ET Company Participants Justine Koenigsberg - Senior Vice President, Investor Relations Roger Tung - President and CEO Marc Becker - CFO Nancy Stuart - COO Jim...

Concert Pharma press release ( NASDAQ: CNCE ): Q2 GAAP EPS of -$0.59 beats by $0.26 . Revenue of $0.02M (-99.9% Y/Y) misses by $0.06M . For further details see: Concert Pharma GAAP EPS of -$0.59 beats by $0.26, revenue of $0.02M misses by $0.06M

CTP-543 Positive Topline Results Reported in THRIVE-AA1 and THRIVE-AA2 Phase 3 Studies in Alopecia Areata CTP-543 Has the Potential to Address an Important Unmet Need for a Large, Underserved Patient Population Conference Call Scheduled Today at 8:30 a.m. ET;...

Clinical-stage biotech Concert Pharmaceuticals ( NASDAQ: CNCE ) traded ~7% higher in the pre-market Monday after the company announced that its second Phase 3 trial for CTP-543 reached primary endpoint with statistical significance in patients with alopecia areata. An au...

THRIVE-AA2 Study Met Primary Endpoint for Scalp Hair Regrowth Key Secondary Endpoint Met for Patient Reported Outcome on Hair Satisfaction Key Secondary Endpoint Met for Hair Regrowth as Early as 12 Weeks CTP-543 Has Potential to be Best-in-Class for the Treatm...

New Online Registration Required for Live Call to Ask Questions Audio-Only Webcast Still Available on Concert’s Website Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its financial results for the second quarter of...

Gainers: Cortexyme (CRTX) +7.9%. GoodRx Holdings (GDRX) +5.4%. Concert Pharmaceuticals (CNCE) +4.9%. Roku (ROKU) +4.3%. Mercer International (MERC) +4.3%. Losers: Rhythm Pharmaceuticals (RYTM) -8.5%. Redbox Entertainment (RDBX) -3.6%. KemPharm (KMPH) -3.1%. SS&C Technologies Hol...